Skip to main content
Erschienen in: Breast Cancer Research 1/2000

01.12.2001 | Paper Report

Duration of adjuvant tamoxifen treatment

verfasst von: Fatima Cardoso

Erschienen in: Breast Cancer Research | Ausgabe 1/2000

Einloggen, um Zugang zu erhalten

Excerpt

The benefits of adjuvant tamoxifen are indisputable; however, its optimal duration is an issue still under discussion. The Oxford Overview analysis, based on 35,000 patients, concludes that five-year treatment is clearly superior to 0-2 years of treatment. Whether a longer period of therapy, namely 10 years, can yield better results is still unknown as the number of patients enrolled in clinical trials (8000) and the median follow-up are still insufficient. Furthermore, the benefits must always be balanced with its potential hazards, namely the increased risk of endometrial cancer that could be related to the duration of therapy. This study investigated the effects of drug treatment after relapse or surgical/radiological treatment. …
Literatur
1.
Zurück zum Zitat Stewart HJ, Prescott RJ, Forrest APM: Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst. 2001, 93: 456-462.CrossRefPubMed Stewart HJ, Prescott RJ, Forrest APM: Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst. 2001, 93: 456-462.CrossRefPubMed
Metadaten
Titel
Duration of adjuvant tamoxifen treatment
verfasst von
Fatima Cardoso
Publikationsdatum
01.12.2001
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 1/2000
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2001-68461

Weitere Artikel der Ausgabe 1/2000

Breast Cancer Research 1/2000 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.